



Figure 1.



3-Haloacetamido benzoyl ethyl ester



3-Haloacetamido benzoylurea

Figure 2




Figure 2

Figure 3




Figure 4




Figure 5




Figure 6




Figure 7.




Figure 8

Halogen	MW	Microtubule Assembly IC50 (uM)	Cancer Cell Cytotoxicity ID50 (uM)
F	233	>100	>79
Cl	241	>100	7.7
Br	253	10	1.9
I	271	2.5	0.17

Figure 9

Human Tissue Type	Cell Line	Cytotoxicity (ug/ml)	
		ID50	ID90
T-cell Leukemia	CEM	0.047	0.1
Myelodysplasia Syndromes	Sp	0.085	0.25
Melanoma	DND-1A	0.25	0.51
Renal Cancer	786-0	0.042	0.08
Breast Cancer	MCF-7	0.12	0.49
Non-small Cell Lung Cancer	NCI-H522	0.05	0.09
Colon Cancer	HCT-116	0.09	0.41
Lymphoma	Daudi/wt*	0.007	0.05
Lymphoma	Daudi/MDR*	0.005	0.06
Normal Lymphocytes	PHA stimulated**	2.5	5.5

Figure 10

Tumor*	Treatment	Number of mice	Therapeutic regime	Tumor bearing mice** (tumor volume**)	Tumor free mice**
Murine EL4 Lymphoma (s.c. implant)	Solvent	15	s.c. injection on day 4,6,8,11,13	15 (2731+/-807)	0
Murine EL4 Lymphoma (s.c. implant)	BAABE	15	s.c. injection on day 4,6,8,11,13	3 (1064+/-411)	12

Figure 11

Compound	Dose (mg/kg)	Treatment Schedule	TI%	TF/T
Control	Diluant*	i.v. day 1,2,3	0	0/10
3-IAABE	15	i.v. daily x4 x2	43	0/10
3-IAABE	25	i.v. 1,2,3	85	2/10
Paclitaxel	30	i.v. q3 x3	90	0/10
Vinblastine	3	i.v. q6d x3	80	0/10